Showing results (991-1000 of 2,735) with videos related to

Sort By:
Pageof 274
Pharmacogenomics|November 20, 2002
Genome research in Austria--a program of the futureMarkus G Pasterk
Pharmacogenomics|November 20, 2002
ExonHit TherapeuticsJim Lyddy
Pharmacogenomics|April 3, 2012
CYP2C19 and PON1 polymorphisms regulating clopidogrel bioactivation in Chinese, Malay and Indian subjectsMark Y Chan, Karen Tan, Huay-Cheem Tan, et al.
Pharmacogenomics|April 3, 2012
Individualized risk for statin-induced myopathy: current knowledge, emerging challenges and potential solutionsQiPing Feng, Russell A Wilke, Tesfaye M Baye
Pharmacogenomics|April 3, 2012
Genetics of ischemic stroke, stroke-related risk factors, stroke precursors and treatmentsDavid Della-Morte, Fiorella Guadagni, Raffaele Palmirotta, et al.
Pharmacogenomics|April 3, 2012
Association of ABCB1 polymorphisms with erlotinib pharmacokinetics and toxicity in Japanese patients with non-small-cell lung cancerAkinobu Hamada, Ji-Ichiro Sasaki, Sho Saeki, et al.
Pharmacogenomics|November 29, 2011
Genetic variants in CYP (-1A2, -2C9, -2C19, -3A4 and -3A5), VKORC1 and ABCB1 genes in a black South African population: a window into diversityCollet Dandara, Zané Lombard, Ingrid Du Plooy, et al.
Pharmacogenomics|June 9, 2012
Impact of the UGT1A1*28 allele on response to irinotecan: a systematic review and meta-analysisMafalda M Dias, Ross A McKinnon, Michael J Sorich
Pharmacogenomics|June 9, 2012
Exploratory planning and implementation of a pilot pharmacogenetic program in a community pharmacyShanna K O'Connor, Stefanie P Ferreri, Natasha M Michaels, et al.
Pharmacogenomics|November 23, 2012
Strengths and weaknesses of pharmacogenetic studies of antipsychotic drugs: the potential value of the PEPs studySergi Mas, Adrián Llerena, Jerónimo Saíz, et al.
Pageof 274